



제 21 회

부산경남내과학회 및
대한내과학회 평생교육
연수강좌

INTERVAL CANCER OF COLON

중간 대장암

Division of gastroenterology

Department of internal medicine

Dong Hoon Baek



목차

- ❖ Detection of CRCs
 - : Prevalence & Screening
- ❖ Interval colon cancer
 - Definition & Taxonomy
 - Prevalence & Risk & Outcome
 - Characteristics
 - Cause
 - Prevention

목차


❖ Detection of CRCs

: Prevalence & Screening

❖ Interval colon cancer

- Definition & Taxonomy
- Prevalence & Risk & Outcome
- Characteristics
- Cause
- Prevention

대 장 암 - 2015년 국가암등록통계 (2017.12.21)



40~49세
29 / 10만명

50~59세
83 / 10만명

60~69세
174 / 10만명

대장암

표 2. 대장암 5년 상대생존율 국제 비교

(단위: %)

	한국('08-'12)	미국('04-'10)	캐나다('06-'08)	일본('03-'05)
전체	74.8	64.7	64.0	69.2


출처: 2012년 국가암등록통계 자료(2014)

localized : 5YSR

94.5%


metastatic : 5YSR

18.6%



대장암 screening

stool occult blood test



Colonoscopy



	ACG (2009)	ACP (2015)	NCCN (2015)	USPSTF (2016)	ACS (2016)
Sigmoidoscopy (yr)	Q 5-10	Q5	Q5	Q 5 or Q 10 + stl	Q5
Colonoscopy (yr)	Q 10	Q10	Q 10	Q 10	Q10
CT colonography (yr)	Q5	N/A	N/A	Q5	Q5
Ba enema (yr)	N/A	N/A	Q5	N/A	Q5
Stool eFOBT (yr)	Q1	Q1	Q1	Q1	Q1
Stool FIT (yr)	Q1	Q1	Q1	Q1	Q1
Stool MT-sDNA (yr)	N/A	N/A	N/A	Q1-3	Q3

대장암 screening : 1. SOBT

대장암 검진 권고안

손대경¹·김민주²·박윤희³·서민아⁴·신애선⁵·이희영⁶·임종필⁷·조현민⁸·홍성필⁹·김백희¹⁰·김용수¹¹·김정욱¹²·김현수¹³·남정모¹⁴·박동일¹⁵·엄준원¹⁶·오순남¹⁷·임환섭¹⁸·장희진¹⁹·함상근²⁰·정지혜²¹·김수영²²·김열²³·이원철²⁴·정승홍²⁵ | 국립암센터¹대장암센터, ²영상의학과, ³가톨릭관동대학교 의과대학 진단검사의학교실, ⁴국립암센터 국가암관리사업본부, ⁵서울대학교 의과대학 예방의학교실, ⁶분당서울대병원 공공의료사업단, ⁷서울대학교 의과대학 내과학교실, ⁸가톨릭대학교 성민센터병원 외과, ⁹연세대학교 의과대학 내과학교실, ¹⁰고려대학교 의과대학 병리학교실, ¹¹한양대학교 의과대학 영상의학교실, ¹²중앙대학교 의과대학 내과학교실, ¹³연세대학교 원주외과대학 내과학교실, ¹⁴연세대학교 의과대학 예방의학교실, ¹⁵성균관대학교 의과대학 강북삼성병원 내과학교실, ¹⁶고려대학교 안산병원 외과, ¹⁷가톨릭대학교 의과대학 방사선과학교실, ¹⁸한진병원 가정의학과, ¹⁹한림대학교 의과대학 강동성심병원 가정의학과, ²⁰가톨릭대학교 의과대학 예방의학교실, ²¹서울대학교 의과대학 외과학교실

The Korean guideline for colorectal cancer screening

SOBT

45~80세의 평균위험군에서 대장암의 선별검사로 기존의 guaiac 대변잠혈검사에 비해 **대변 면역화학검사**를 우선적으로 권고.

	대장암진단 민감도	대장암진단 특이도
guaiac SOBT	79.4%	88.1%
FIT	73%	94.8%

대장암 사망을 감소 : 15~33%

대요마 야마통 마주 : 12~33%



대장암 screening : 2. 대장내시경

Korean J Gastroenterol Vol. 59 No. 2, 65-84
<http://dx.doi.org/10.4166/kjg.2012.59.2.65>

SPECIAL REVIEW

KJG

대장암 선별과 대장폴립 진단검사 가이드라인

Colonoscopy

50세 이상의 평균위험군에서 **대장암 선별과 대장샘종의 진단 검사**로 **대장내시경검사를** 우선적으로 권고한다.

- 중대한 합병증의 발생률 : 0~0.47%
- 사망의 발생률 : 0~0.06%

Follow-up Time	Adenoma Cohort			General Population			P Value
	No.	Person-Years at Risk	Observed Deaths <i>no.</i>	Expected Deaths <i>no.</i>	SMR (95% CI)	Reduction %	
All	2602	37,073	12	25.4	0.47 (0.26-0.80)	53	0.008
<10 yr	2602	22,903	4	9.1	0.44 (0.14-1.06)	56	0.09
≥10 yr	2031	14,170	8	16.3	0.49 (0.23-0.93)	51	0.04

대장암 발생을 감소 : **76~90%**

대장암 사망을 감소 : **65%**


목차

❖ Detection of CRCs


: Prevalence & Screening

❖ **Interval colon cancer**



- **Definition & Taxonomy**
- Prevalence & Risk & Outcome
- Characteristics
- Cause
- Prevention




No abnormal finding on A.C
10mm 이상, 4개의 LGD
on Rectosigmoid lesion



2년 후 Anemia, RLQ pain





2012.3.19

2014.11.25

2015.3.19

High risk

중간 대장암
Interval cancer of colon
Postcolonoscopy colorectal cancers (PCCRC)

Failure of colonoscopy to detect colorectal cancer: evaluation of 47 cases in 20 hospitals

GASTROINTESTINAL ENDOSCOPY
VOLUME 45, NO. 6, 1997

Joseph H. Haseman, MD, Gregory T. Lemmel, MD, Emad Y. Rahmani, MD, Douglas K. Rex, MD

Indianapolis, Indiana





Figure 1. Location of colorectal cancers "missed" (□) and "not reached" (○). CEC, Cecum; ASC, ascending; HF, hepatic flexure; TRA, transverse; SF, splenic flexure; DES, descending; S, sigmoid; REC, rectum.

Study	Subjects	Prevalence	Major findings
Farrar et al. ¹⁴ (2006)	Clinical record of veterans (n=830)	5.4%	27% of interval cancers developed at previous polypectomy segments
Bressler et al. ¹⁵ (2007)	Claims-based administrative data (n=31,074)	3.4%	2.1% in the left colon vs. 5.9% in the right colon
Lakoff et al. ¹⁶ (2008)	Claims-based administrative data (n=111,402)	1.3% vs. 2.2%	Negative colonoscopy has a protective effect for CRC (1.3% vs. 2.2%)
Kahi et al. ⁸ (2009)	Asymptomatic screening cohorts (n=715)	1.7%	48-67% CRC reduction with screening colonoscopy
Kaminski et al. ¹⁷ (2010)	National CRC screening program in Poland (n=45,026)	0.09%	Association of interval cancer risk with ADR
Mulder et al. ¹⁸ (2010)	Administrative primary care data (n=457,014)	2.9% vs. 4.4%	Protective effect with previous examinations for CRC (2.9% vs. 4.4%)
Singh et al. ¹² (2010)	Manitoba Cancer Registry database (n=4,833)	7.9%	4.5% in the left colon vs. 14.4% in the right colon
Singh et al. ¹⁹ (2010)	Manitoba database (n=45,985)	3.0%	0.6% in the left colon vs. 2.1% in the right colon
Baxter et al. ²⁰ (2011)	Claims-based administrative & cancer registry (n=14,064)	9.0%	6.8% in the left colon vs. 12.4% in the right colon
Cooper GS et al. ¹¹ (2012)	SEER database (n=57,839)	7.2%	2.9% in the left colon vs. 4.9% in the right colon
Brenner et al. ²¹ (2012)	Population-based case-control study (CRC n=1,945)	4.0%	Substantial proportion of interval cancers are due to missed lesions
Horiuchi et al. ²² (2012)	Single center colonoscopy registry (n=3,212)	0.3%	2.3% in the left colon vs. 13.3% in the right colon, Japanese data
Huang et al. ²³ (2012)	Post-polypectomy surveillance data (n=1,794)	0.8%	2.9 cases/1,000 person-year in follow up colonoscopy
Kim et al. ²⁴ (2013)	Single center CRC registry (CRC n=482)	6.2%	2.5% in the left colon vs. 3.3% in the right colon, Korean data
Erichsen et al. ²⁵ (2013)	Population-based cohort study (CRC n=36,686)	2.6%	Majority interval cancers may be missed lesions, without aggressive biology
Samadder et al. ²⁶ (2014)	Population-based study (n=126,851, CRC n=2,659)	6.0%	Right colon location (OR 2.24) family history of CRC (OR 2.27)

1
2
3

Colorectal cancer diagnosed after a colorectal **screening** examination or test in which **no cancer** is detected, and before the date of the **next recommended exam**.




Colorectal cancer diagnosed after a colorectal **screening** examination or test in which **no cancer** is detected, and before the date of the **next recommended exam**.

- **(1) Screen-detected CRC**

: cancers diagnosed within the screening programme, and at a defined period after a positive screening test/examination

- **(2) Non-screen-detected CRC**

: cancers in individuals who are not compliant with screening



1

2

3

FIT screen-detected cancer

FIT interval cancer

CS interval cancer

1

2

3

FIT screen-detected cancer

- 60세 여자. **annually FIT**
- **2년 전까지** 2회의 annual FIT 검사 **negative**
(last screening : 2016.3월)
- **2017.3월 FIT 검사 positive**
=> **대장내시경** 시행 후 **대장암** 진단받음.

FIT interval cancer

CS interval cancer

1

2

3

FIT screen-detected cancer

FIT interval cancer

- 57세 남자. **annually FIT**
- 2016.3월 FIT 검사에서 **negative**
- **2016.11월 혈변**으로 내원 => **대장내시경**
검사에서 **대장암 진단**

CS interval cancer

1

2

3

FIT screen-detected cancer

FIT interval cancer

CS interval cancer

- 67세 남자.
- 2015년 대장내시경검사에서 정상
=> 5년 후 CS f-u 권고 받음.
- 2017년 rectal bleeding으로 내원
=> 대장내시경검사에서 Rectosigmoid colon ca. 진단.

1

2

3

FIT screen-detected cancer

FIT interval cancer

CS interval cancer ???

- 75세 남자.
- 2013년 대장내시경검사에서 4개의 adenomatous polyip => 3년 후 대장내시경 f-u 권고 받음.
- 2015년 M.I => PCI 시행 후 대장내시경 받지 못함.
- 2017년 rectal blood loss => 대장내시경 검사에서 상행결장암 진단됨.



목차

❖ Detection of CRCs

: Prevalence & Screening

❖ **Interval colon cancer**

- Definition & Taxonomy
- **Prevalence & Risk & Outcome**
- Characteristics
- Cause
- Prevention


1

Prevalence of interval CRC = **1.8 ~ 9.0 %**

On pooled analysis, the prevalence of interval CRCs
= **4.3 %** (95 % CI = 2.6-6.9 %) within 6~60 months

2

3




1

Prevalence of interval CRC in KOREA = **6.2 %**

2

3

**2007~2012. Retrospective, 3RD Referral center
Telephone interview**




1

2

3



Clinical factor



Endoscopy-related factor




Biology-related factor



<<Clinical factor>>

- ① **Old age** : > 65~70yr vs. < 65~70yr
[OR = 1.12, 95% CI: 1.02-1.30]
- ② **Family Hx.** : 1.6배 (OR = 1.64, 95% CI: 1.40-1.90)
- ③ **Multiple Comorbidity** : 2배 (OR = 2.0, 95% CI: 1.77-2.27)
- ④ **Diverticular Ds.** : 4.3배 (OR = 4.25, 95% CI: 2.58-7.00)
- ⑤ **Polypectomy at Index CS** : 1.6배 (OR = 1.57, 95% CI: 0.97-2.56)




<<Endoscopy-related factor>>

- ① Non-gastroenterologist (internist/F.M) vs. Gastroenterologist
OR = 1.53, 95% CI: 1.32–1.77
Surgeon vs. Gastroenterologist
OR = 1.15, 95% CI: 0.96–1.49
- ② procedure completion rates and polypectomy rate
OR = 0.70, 95 %CI = 0.63 – 0.77

검사자의 숙련도

최소 400예 이상의 경험
매년 200예의 검사 시행



<<Biology-related factor>>

① CpG island methylator phenotype

(CIMP; OR = 2.19, 95 % CI: 1.14–4.21)

② microsatellite instability

(MSI; OR = 2.10, 95 % CI = 1.10 – 4.02)

1

2

3

1

2

3

Stage and grade of CRCs

- ✓ interval CRCs were less likely to be diagnosed at an advanced stage (stage III or IV; OR = 0.79)
- ✓ interval CRCs were just as likely as detected CRCs to be well- to moderately differentiated (G1 / G2: OR = 0.87)

Survival of interval CRCs

As compared with detected CRCs, interval CRCs did not show differences in **5-year survival** of patients.

목차

❖ Detection of CRCs

: Prevalence & Screening

❖ Interval colon cancer

- Definition & Taxonomy
- Prevalence & Risk & Outcome
- **Characteristics**
- Cause
- Prevention

- ① Proximal colon >> Distal colon (OR 3.92, 95% CI 2.7-5.6)
- ② Flat appearance (OR 1.70, 95% CI 1.1-2.4)
- ③ Small sized (OR 0.78, 95% CI 0.7-0.8)

Table 3 Multiple logistic regression analysis adjusting for age and gender to examine risk factors for postcolonoscopy colorectal cancers (PCCRC)

Postcolonoscopy vs prevalent CRCs*	OR	95% CI	p Value
Proximal location (vs distal)	3.92	2.71 to 5.69	<0.001
Size in cm (continuous)	0.78	0.70 to 0.87	<0.001
Flat appearance (vs protruded)	1.70	1.18 to 2.43	0.004
≥50% mucinous histology (vs <50%)	1.61	0.94 to 2.76	0.085
Specialty of endoscopist (gastroenterologist vs non-gastroenterologist)	1.33	0.81 to 2.19	0.266
Hospital setting (university vs non-university hospital)	1.22	0.82 to 1.83	0.333


*Adjusted for age and gender.
CRC, colorectal cancer.

- ① Proximal colon >> Distal colon (OR 3.92, 95% CI 2.7-5.6)
- ② Flat appearance (OR 1.70, 95% CI 1.1-2.4)
- ③ Small sized (OR 0.78, 95% CI 0.7-0.8)

Proximal colon



- Worse bowel preparation
- More incomplete colonoscopies
- More difficult to examine
- Flat lesions



목차

❖ Detection of CRCs

: Prevalence & Screening

❖ Interval colon cancer

- Definition & Taxonomy
- Prevalence & Risk & Outcome
- Characteristics
- **Cause**
- Prevention

missed lesion




52%

Incomplete Rx.



19%

New lesions




24%



1

missed lesion



52%

Miss rate (overall = 21%)

: Adenomas = 20-24%, Polyps = 22-28%

① **Size**

1~5mm = 26%

5~9mm = 13%,

≥ 10mm = 2%


② **Morphology** : Flat / Sessile

③ **Total number** : ≥ 3

④ **Poor Bowel prep.**

1
2
3

missed lesion




52%

① Withdrawl time



	6분 미만	6분 이상
ADR	11.8 ± 2.2	28.3 ± 4.0
Advanced neoplasia	2.6 ± 1.1	6.4 ± 1.7

② Suboptimal observation techniques


- : Adequate cleansing, Adequate distension,
- Looking on prox. side of folds
- Adequate of time spent view



2014 Descending colon ca.
=> Lt. hemicolectomy





2016 f-u Colonoscopy
: Post OP colon
(s/p Lt. hemicolectomy
d/t D-Colon ca.)




2014 Descending colon ca.

: D-colon ca. Lt. hemicolectomy




2017 f-u Colonoscopy


: Interval cancer on HF



2015 Descending colon ca.
: D-colon ca. Lt. hemicolectomy




2016 f-u Colonoscopy




2017 f-u CS


대장내시경 맹점부위



The oral side of haustra in the ascending colon.




Human Eye Anatomy





Incomplete Rx.



19%

Result of the Complete Adenoma Resection [CARE] study

Pathologically incomplete resection rate = **10.1%**

① Size

: **10-20mm** vs. <10mm : **17%** vs. 6.8%

② Histology

: **SSA/P** vs. Adenoma : **31%** vs. 7.2%




1
2
3

Incomplete Rx.





19%


① Piecemeal Rx. (large sessile polyp ≥ 2 cm)
: mean recurrence rate = 25% (0~55%)







: Endoscopist technique







Local H. : LST => incomplete Rx




PNUH Referral




**Incomplete resected LST
/c scar change => ESD
: T.A /c LGD**



F-U Colonoscopy after 6 month.



LST의 Margin은 ?



Clinicopathological, endoscopic, and molecular characteristics of the “skirt” – a new entity of lesions at the margin of laterally spreading tumors



(1) Higher rate of **ADC**

:LST /c skirt : 80% vs. LST /s skirt : 45.4%


(2) Higher possibility of **Incomplete Rx.**

:Interval cancer의 원인



1
2
3

New lesions



24%

Interval cancer

: Proximal colon / Flat appearance / large sized

=> Serrated pathway

Missed lesion

flat, mucous cap



Incomplete resection

vague margin




Two of following features:

- Clouded surface?
- Indistinctive border?
- Irregular shape?
- Dark spots inside crypts?



1
2
3




Molecular feature of the serrated pathway

- ① **BRAF mutation : 78~90%**
: MAPK pathway activation -> cell prolif. & survival
: **MVHP -> Serrated Lesion**
- ② **CIMP (with or without MSI) : 70%**
: loss of suppressor gene <= associated with mBRAF
(MGMT, MLH1, p16, MINT1, MINT2, and MINT31 genes)
❖ **DNA mismatch repair (MMR) gene silencing** by
methylation (**MSI-H, 4배**) / **p53 mutation**
= **Rapid progression of serrated polyps to cancers**



1
2
3




Clinicopathological Characteristics of Interval and Sporadic Cancers

Characteristic	Interval cancer (n=25)	Sporadic cancer (n=261)	p-value
Tumor size, cm	3.8±2.4	4.3±2.0	0.260
Location (proximal) [*]	13 (52)	77 (29)	0.020
MSI positivity [†]	8 (32)	22 (8.4)	0.002
TNM stage			0.055
1	9 (36)	55 (21)	
2	8 (32)	72 (27)	
3	6 (24)	101 (38)	
4	2 (8)	33 (12)	
Histologic grade			0.230
Well	3 (13)	14 (5)	
Moderate	19 (86)	232 (91)	
Poor	0	7 (3)	
Mucinous [‡]	3 (12)	8 (3)	0.060




1
2
3

New lesions



24%

Normal mucosa
In the proximal
colon



ACF



MVHP




SSA/P



SSA/P with cytological
dysplasia or cancer



MSI-H cancer
or
MSS cancer



MLH1 methylation and/or p53 mutation

serration


: increased turn over, delayed migration, suppressed apoptosis

V. Cause - new lesions




1
2
3

New lesions






24%







serration

: increased turn over, delayed migration, suppressed apoptosis



ADC arising from SSA/P






Early Colon Cancer : mod. diff. ADC

Size of whole tumor : 1.8x1.7cm

Size of invasive carcinoma : 0.8x0.8cm

Tumor invades **submucosa** (pT1).

* Depth of invasion : 4000um / 4750um



* Additional Pathologic Findings

- **Sessile serrated adenoma**
with high grade dysplasia.

목차

❖ Detection of CRCs

: Prevalence & Screening

❖ Interval colon cancer

- Definition & Taxonomy
- Prevalence & Risk & Outcome
- Characteristics
- Cause
- **Prevention**

Failure of colonoscopy to detect colorectal cancer: evaluation of 47 cases in 20 hospitals

GASTROINTESTINAL ENDOSCOPY
VOLUME 45, NO. 6, 1997

Joseph H. Haseman, MD, Gregory T. Lemmel, MD, Emad Y. Rahmani, MD, Douglas K. Rex, MD

Indianapolis, Indiana





Figure 1. Location of colorectal cancers "missed" (□) and "not reached" (○). CEC, Cecum; ASC, ascending; HF, hepatic flexure; TRA, transverse; SF, splenic flexure; DES, descending; S, sigmoid; REC, rectum.

1

2

❖ Colonoscopy Quality is the Answer for the Emerging Issue of Interval Cancer !!!



Bowel prep.

Adequate bowel prep.

≥ 85%

고령 / comorbid condition

Split dose vs. same day

satisfactory prep : 3.7배
willingness to repeat : 1.8배

Cecal intubation rate

Cecal intubation rate

≥ 90% (all exam)

≥ 95% (screening CS)

여성 (longer/redundant) / 고령
복부 또는 골반 내 수술의 과거력

Reattempt / Referral

지속적인 교육

ADR

Adenoma detection rate

overall target ≥ 25%

≥ 30% for male

≥ 20% for female

ADR 1% ↑
: CRC incidence 3% ↓
: Mortality 5% ↓

❖ Follow-up/surveillance recommendations





Table 2 Recommendation for surveillance intervals of serrated polyps (revised from Lieberman *et al.*³²)

Baseline colonoscopy: most advantage findings	Recommended surveillance
No polyps	10
Small (< 10 mm) hyperplastic polyps in rectosigmoid	10
Sessile serrated polyps < 10 mm with no dysplasia	5
Sessile serrated polyps ≥ 10 mm	3
Sessile serrated polyps with dysplasia	3
Traditional serrated adenoma	3
Serrated polyposis syndrome	1



Interval cancer 발생 줄이기

Colonoscopy Quality is the Answer for the Emerging Issue of Interval Cancer !!!



중간암 감소 ↓

완벽한 대장내시경 ↑

Thank you for your attention.

